METACLIPSE THERAPEUTICS CORP — Department of Health and Human Services SBIR Phase II: NIAID
METACLIPSE THERAPEUTICS CORP — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $1,948,234, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code NIAID links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $1,948,234
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NIAID
- NAICS
- —
- Place of performance
- GA
- Period
- —
Description
lnterleukinILand granulocyte macrophage colony stimulating factorGM CSFare endogenous immune activatorsEarlier studies using soluble ILand GM CSF as vaccine adjuvants were unsuccessful due to toxicity or suboptimal responseWe developed versions of ILand GM CSF with a glycosylated phosphatidylinositolGPIanchor added at the carboxyl terminusallowing incorporation into lipid bilayers such as in influenza virus like particlesVLPsPrevious studies in young and aged mice using GPI GM CSF and GPI ILincorporated influenza HVLPs induced strong humoral and cellular immunity that protected both young and aged mice from homologous and heterologous viral challengeCurrentlyelderly patients fail to respond well to influenza vaccinesIn this phase II proposal we will evaluate dose response and dose scheduling of the GPl cytokine incorporated VLPs to determine the minimum anticipated biological effect levelMABELdose to induce a protective immune response in miceThis proposal will also evaluate the safety of the vaccine in murine and monkey modelsBenchmarks required for cGMP compliant vaccine production and characterization will also be determinedThis study will contribute to the development of safe and effective adjuvant combinations that can be used to enhance the efficacy of influenza and other antiviral vaccines critically needed for the elderly